How Will the Non-Alcoholic Steatohepatitis Biomarkers Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the non-alcoholic steatohepatitis biomarkers market grown in recent years?
The market size for non-alcoholic steatohepatitis biomarkers has experienced tremendous growth recently. The market is predicted to increase from a value of $1.36 billion in 2024 to about $1.7 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 24.8%. This remarkable growth during the historic period can be linked to various factors such as diabetes and metabolic syndrome, increased awareness and enhanced screening programs, limitations of liver biopsies, supportive regulations, a move towards personalized medicine and clinical trials focusing on NASH.
How is the non-alcoholic steatohepatitis biomarkers market size expected to evolve during the forecast period?
In the coming years, rapid growth is predicted for the non-alcoholic steatohepatitis biomarkers market, with an expected rise to $3.86 billion by 2029, following a compound annual growth rate (CAGR) of 22.8%. This increase in the projection period, can be attributed to the development of new therapies, the broadening of precision medicine, patient advocacy drives, the addition of multi-omics data, and better patient participation. Key trends during the forecast period will incorporate telemedicine and distance monitoring, novel diagnostic platforms, international research collaborations, technological progress in biomarker identification, integration of AI, and the introduction of imaging biomarkers.
Get your non-alcoholic steatohepatitis biomarkers market report here!
Which key drivers are propelling the non-alcoholic steatohepatitis biomarkers market’s growth?
The escalating incidence of liver cancer is expected to boost the expansion of the non-alcoholic steatohepatitis biomarkers market. Liver cancer constitutes the formation of malignant growths within the liver, originating either from the liver directly, termed primary liver cancer, or spreading from other body parts, known as secondary or metastatic liver cancer. Non-alcoholic steatohepatitis (NASH) biomarkers play a vital role in liver cancer for early identification, observation of disease progress, and assessing the response to treatment. It significantly contributes to providing predictive insights and curbing the necessity for invasive procedures. For instance, in 2022, as reported by the World Cancer Research Fund, a non-profit UK-based establishment, about 866,136 new liver cancer cases were recorded worldwide, making liver cancer the 6th most prevalent cancer globally. Hence, the surge in liver cancer incidence is stimulating the expansion of the non-alcoholic steatohepatitis biomarkers market.
What are the market segments in the non-alcoholic steatohepatitis biomarkers industry?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
Which leading companies are shaping the growth of the non-alcoholic steatohepatitis biomarkers market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
What key trends are currently impacting the non-alcoholic steatohepatitis biomarkers market’s development?
Emerging technology is a prevalent trend in enhancing the profile of the non-alcoholic steatohepatitis biomarkers market. The prominent players in this market are focusing their efforts on creating innovative solutions to solidify their industry standing. A case in point involves a five-year exclusive licensing agreement struck in October 2022 between GENFIT, a late-stage biopharmaceutical firm based in France, and LabCorp, a US-based company operating in the life sciences sector. This agreement involves GENFIT’s pioneering NIS4 tech, explicitly designed to identify patients with non-alcoholic steatohepatitis (NASH) who have significant to advanced fibrosis (F > 2), also known as at-risk NASH. LabCorp is set to create and market a blood-based molecular diagnostic examination using NIS4 technology, providing broad access for healthcare professionals within the US and Canada.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9002
Which geographic areas are influencing the growth of the non-alcoholic steatohepatitis biomarkers market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Alcoholic – Beverages Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report
Food And Beverages E-Commerce Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/food-and-beverages-ecommerce-global-market-report
Prosthetic Heart Valve Devices And Equipment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
